About Humanwell Healthcare Company

Established in 1993 and listed on the Shanghai Stock Exchange in 1997, it is a leading enterprise in the pharmaceutical industry in Hubei Province, China's top 30 pharmaceutical industry, a national scientific and technological innovation demonstration enterprise, and a leading enterprise in the internationalization of Chinese pharmaceutical preparations. It has formed a leading or leading position in segments such as neurological medicine, steroid hormone drugs, and Uyghur folk medicine, and has gradually expanded the generic drug business in the US in recent years. It is mainly engaged in R&D, production and sales of pharmaceuticals, and is a leading enterprise in the pharmaceutical industry in Hubei Province and a national technological innovation demonstration enterprise. The main products include fentanyl citrate injections, sufentanyl citrate injections, remifentanil hydrochloride injections, hydromorphone hydrochloride injections, nalbuphine hydrochloride injections, etc. Corporate honors: The company has been selected by the Ministry of Industry and Information Technology's “China's Top 100 Pharmaceutical Industry List” for 13 consecutive years, and selected as the “2022 China Top 500 Manufacturing Enterprises”.